{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:22:20Z","timestamp":1794885740081,"version":"4.9.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [<jats:sup>68<\/jats:sup>Ga]DOTATATE and [<jats:sup>18<\/jats:sup>F]FDG PET\/CT scans. We aimed to validate previous single-centre findings in a multicentre, international study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Dual scans were assigned a NETPET score of P1 (DOTATATE positive\/FDG negative), P2\u20134 (DOTATATE positive\/FDG positive), or P5 (DOTATATE negative\/FDG positive). NETPET score, histological grade, age at diagnosis, and presence\/absence of extrahepatic disease were compared to overall survival\/time to progression on univariate and multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>319 metastatic\/unresectable GEPNEN patients were included. The NETPET score was significantly associated with overall survival and time to progression on univariate and multivariate analysis (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Median overall survival\/time to progression was 101.8\/25.5 months for P1, 46.5\/16.7 months for P2\u20134, and 11.5\/6.6 months for P5. Histological grade correlated with overall survival and time to progression on univariate and multivariate analysis (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), while presence\/absence of extrahepatic disease did not. Age at diagnosis correlated with overall survival on univariate and multivariate analysis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The NETPET score also correlated with histological grade (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study validates the NETPET score as a prognostic biomarker in metastatic GEPNENs, capturing the complexity of dual PET imaging.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-02061-5","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T19:57:28Z","timestamp":1669406248000},"page":"549-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score"],"prefix":"10.1038","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-3144","authenticated-orcid":false,"given":"David L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee R.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-1582","authenticated-orcid":false,"given":"Alice","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Furtado O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Mileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenna\u00eblle","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Schembri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Gnanasegaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vanderlinden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn E.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2061_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"2061_CR2","unstructured":"Klimstra DS, Kloppell G, La Rosa S, WHO Classification of Tumours Editorial Board. Classification of neuroendocrine neoplasms of the digestive system. WHO classification of tumours: digestive system tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2019, 16."},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra DS, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","journal-title":"Histopathology"},{"key":"2061_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1159\/000504392","volume":"110","author":"J Botling","year":"2020","unstructured":"Botling J, Lamarca A, Bajic D, Norl\u00e9n O, L\u00f6nngren V, Kjaer J, et al. High-grade progression confers poor survival in pancreatic neuroendocrine tumors. Neuroendocrinology. 2020;110:891\u20138.","journal-title":"Neuroendocrinology."},{"key":"2061_CR5","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","volume":"55","author":"H Bahri","year":"2014","unstructured":"Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786\u201390.","journal-title":"J Nucl Med"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, et al. 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study. J Nucl Med. 2021;62:808\u201315.","journal-title":"J Nucl Med"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2967\/jnumed.109.066662","volume":"51","author":"D Campana","year":"2010","unstructured":"Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AMM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353\u20139.","journal-title":"J Nucl Med"},{"key":"2061_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, W\u00e4ngler B, Schmidt GP, Uebleis C, G\u00f6ke B, et al. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349\u201356.","journal-title":"J Nucl Med"},{"key":"2061_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","volume":"141","author":"R Sharma","year":"2019","unstructured":"Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. 68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108\u201315.","journal-title":"Radiother Oncol"},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149\u201358.","journal-title":"Theranostics."},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.18632\/oncotarget.27460","volume":"11","author":"I Karfis","year":"2020","unstructured":"Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, et al. Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias. Oncotarget. 2020;11:589\u201399.","journal-title":"Oncotarget."},{"key":"2061_CR12","first-page":"26","volume":"47","author":"AR Hayes","year":"2022","unstructured":"Hayes AR, Furtado O\u2019Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, et al. The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact. J Clin Med. 2022;47:26\u201335.","journal-title":"J Clin Med"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RLU.0000000000003937","volume":"47","author":"AR Hayes","year":"2022","unstructured":"Hayes AR, Furtado O\u2019Mahony L, Quigley AM, Gnanasegaran G, Caplin ME, Navalkissoor S, et al. The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system with prognostic impact. Clin Nucl Med. 2022;47:26\u201335.","journal-title":"Clin Nucl Med"},{"key":"2061_CR14","doi-asserted-by":"crossref","unstructured":"Chan DL, Hayes AR, Karfis I, Navalkissoor S, Furtado O\u2019Mahony L, Conner A, et al. Dual 68Ga-DOTATATE and 18F-FDG PET\/CT in patients with gastroenteropancreatic neuroendocrine neoplasms: a multicentre, validation study of the NETPET score in 239 patients. J Neuroendocrinology. 2021;S1 abstract K11:178.","DOI":"10.1038\/s41416-022-02061-5"},{"key":"2061_CR15","doi-asserted-by":"crossref","unstructured":"Chan DL, Ulaner GA, Pattison DA, Wyld D, Ladwa R, Kirchner J, et al. Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker. J Nucl Med. 2021;62:1278\u201384.","DOI":"10.2967\/jnumed.120.257659"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00259-020-04915-7","volume":"48","author":"L Zidan","year":"2021","unstructured":"Zidan L, Iravani A, Kong G, Akhurst T, Michael M, Hicks RJ. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:204\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2061_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/jcm8071032","volume":"8","author":"L Carideo","year":"2019","unstructured":"Carideo L, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, et al. Role of combined [68 Ga]Ga-DOTA-SST analogues and [18 F]FDG PET\/CT in the management of GEP-NENs: a systematic review. J Clin Med. 2019;8:1032.","journal-title":"J Clin Med"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40336-019-00328-1","volume":"7","author":"F Muffatti","year":"2019","unstructured":"Muffatti F, Partelli S, Cirocchi R, Andreasi V, Mapelli P, Picchio M, et al. Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clin Transl Imaging. 2019;7:181\u20138.","journal-title":"Clin Transl Imaging"},{"key":"2061_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2967\/jnumed.118.224386","volume":"60","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, Huizing DMV, Walraven I, de Wit-van der Veen BJ, Kulkarni HR, Singh A, et al. Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients. J Nucl Med. 2019;60:1259\u201365.","journal-title":"J Nucl Med"},{"key":"2061_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","volume":"154","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, et al. Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors. Gastroenterology. 2018;154:998\u20131008.e1.","journal-title":"Gastroenterology"},{"key":"2061_CR21","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","volume":"46","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46:2244\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02061-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T16:15:00Z","timestamp":1676650500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02061-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,16]]}},"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02061-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DLC reports honoraria from Ipsen and Novartis; and research support from EMD Serono, outside the submitted work. NP reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Serono, Ipsen, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Roche Pharma AG, Merck, Baxalta, and Specialised Therapeutics, outside the submitted work. GG reports personal fees from AAA, outside the submitted work. SN reports personal fees from AAA, outside the submitted work. MC reports personal fees from Ipsen, Novartis, AAA, Lexicon, and Pfizer, and grants from AAA and Ipsen, outside the submitted work. CT reports personal fees from Ipsen, Novartis, and AAA, education grants from Ipsen, Novartis and AAA, outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the relevant ethics committee for each centre: Northern Sydney Local Health District Human Research Ethics Committee [2019\/ETH14060], the Royal Free Hospital NHS Foundation Trust Quality Governance and Clinical Audit Committee, and the Ethics Committee of Jules Bordet Institute [CE2531]. Each committee waived the need for informed consent. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}